CL2025000596A1 - Formas co-cristalinas de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y/o nicotinamida. - Google Patents

Formas co-cristalinas de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y/o nicotinamida.

Info

Publication number
CL2025000596A1
CL2025000596A1 CL2025000596A CL2025000596A CL2025000596A1 CL 2025000596 A1 CL2025000596 A1 CL 2025000596A1 CL 2025000596 A CL2025000596 A CL 2025000596A CL 2025000596 A CL2025000596 A CL 2025000596A CL 2025000596 A1 CL2025000596 A1 CL 2025000596A1
Authority
CL
Chile
Prior art keywords
pyrazolo
carbonitrile
triazol
pyridin
piperidine
Prior art date
Application number
CL2025000596A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Coates David
Raquel Hilden Lori
Kuminek Gislaine
a peterson Jeffrey
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2025000596A1 publication Critical patent/CL2025000596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2025000596A 2022-09-07 2025-03-04 Formas co-cristalinas de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y/o nicotinamida. CL2025000596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263404232P 2022-09-07 2022-09-07

Publications (1)

Publication Number Publication Date
CL2025000596A1 true CL2025000596A1 (es) 2025-04-25

Family

ID=88204177

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025000596A CL2025000596A1 (es) 2022-09-07 2025-03-04 Formas co-cristalinas de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y/o nicotinamida.

Country Status (18)

Country Link
US (1) US12662483B2 (cg-RX-API-DMAC7.html)
EP (1) EP4584270A1 (cg-RX-API-DMAC7.html)
JP (2) JP7541606B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250057022A (cg-RX-API-DMAC7.html)
CN (1) CN120187720A (cg-RX-API-DMAC7.html)
AR (1) AR130417A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023338199B2 (cg-RX-API-DMAC7.html)
CA (1) CA3266872A1 (cg-RX-API-DMAC7.html)
CL (1) CL2025000596A1 (cg-RX-API-DMAC7.html)
CO (1) CO2025002467A2 (cg-RX-API-DMAC7.html)
CR (1) CR20250077A (cg-RX-API-DMAC7.html)
DO (1) DOP2025000054A (cg-RX-API-DMAC7.html)
IL (1) IL319342A (cg-RX-API-DMAC7.html)
JO (1) JOP20250053A1 (cg-RX-API-DMAC7.html)
MX (1) MX2025002687A (cg-RX-API-DMAC7.html)
PE (1) PE20251400A1 (cg-RX-API-DMAC7.html)
TW (1) TWI862146B (cg-RX-API-DMAC7.html)
WO (1) WO2024054814A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259519A1 (en) 2024-06-13 2025-12-18 Eli Lilly And Company Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3)
WO2026037249A1 (zh) * 2024-08-13 2026-02-19 海思科医药集团股份有限公司 取代杂环类衍生物及其用途
WO2026084690A1 (en) * 2024-10-14 2026-04-23 Eli Lilly And Company Fgfr3 inhibitor dosing regimens for use in treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163790B2 (en) * 2005-12-08 2012-04-24 New Form Pharmaceuticals, Inc. Metronidazole cocrystals and imipramine cocrystals
PH12012000132B1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
CN102964384B (zh) * 2012-11-09 2015-06-24 中山大学 阿德福韦酯没食子酸共晶及其制备方法和组合物
EP3752159A4 (en) * 2018-02-13 2021-11-24 Transgenex Nanobiotech, Inc. NEW CRYSTALLINE FORMS OF TAMIBAROTENE FOR CANCER TREATMENT
WO2020131627A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN111574359A (zh) * 2019-02-19 2020-08-25 愈磐生物科技(苏州)有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN113943284B (zh) * 2020-07-15 2023-12-19 中国医学科学院药物研究所 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途
AR125588A1 (es) * 2021-03-04 2023-08-02 Lilly Co Eli Compuestos inhibidores de fgfr3

Also Published As

Publication number Publication date
DOP2025000054A (es) 2025-03-31
AU2023338199A1 (en) 2025-03-20
EP4584270A1 (en) 2025-07-16
JP2024037713A (ja) 2024-03-19
AU2023338199B2 (en) 2026-07-16
US12662483B2 (en) 2026-06-23
AR130417A1 (es) 2024-12-04
JP2024153948A (ja) 2024-10-29
CA3266872A1 (en) 2024-03-14
WO2024054814A1 (en) 2024-03-14
CR20250077A (es) 2025-04-02
JOP20250053A1 (ar) 2025-03-06
CO2025002467A2 (es) 2025-03-17
US20240116932A1 (en) 2024-04-11
TW202428260A (zh) 2024-07-16
KR20250057022A (ko) 2025-04-28
TWI862146B (zh) 2024-11-11
CN120187720A (zh) 2025-06-20
MX2025002687A (es) 2025-04-02
JP7541606B2 (ja) 2024-08-28
IL319342A (en) 2025-05-01
PE20251400A1 (es) 2025-05-22

Similar Documents

Publication Publication Date Title
CO2025002467A2 (es) Derivados de co-cristales de 4-[4-[3-cloro-4-[1-(2- piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5- metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y amida nicotínica
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CO2023008167A2 (es) Inhibidores de prmt5
Moretti et al. TNF-α-induced depressive-like phenotype and p38MAPK activation are abolished by ascorbic acid treatment
GT200900056A (es) Benzoxazoles y oxazolopiridinas utiles como inhibidores de la quinasa janus
EP4360713A3 (en) Quinazoline derivatives as antitumor agents
MX2019013260A (es) Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas.
CL2011000880A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidin-3-il, inhibidores de tirosina de la familia trk cinasa; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del dolor y del cancer.
MX2021009444A (es) Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7.
CL2025004052A1 (es) Derivados pirazolo[3,2-c]piridinona, inhibidores egfr y/o her2; composición; uso en cáncer
MX2023005626A (es) Derivados de pirazolo[1.5-a]pirazina como inhibidores de la btk.
UY37559A (es) Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
ECSP22009803A (es) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas
AR132251A1 (es) Derivados de 5-amino-6,8-dihidro-1h-furo[3,4-d]pirrolo[3,2-b]piridin-2-carboxamida como inhibidores cooperativos con mta de prmt5
CL2024003731A1 (es) Compuestos tricíclicos de triazolo, inhibidores de dgk; uso para tratar cáncer.
BR112023011451A2 (pt) Inibidores de alk-5 e seus usos
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
CL2024003643A1 (es) Macrociclos de indazol y su uso.
UY31866A (es) Combinaciones farmacéuticas comprendiendo los compuestos 3-z[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilene]-6-metoxicarbonil-2-indolinona y el ácido n-[4-[2-(2-amino-4,7-dihidro-4-oxo-1h-pirrolo [2,3-d] pirimidin-5-il)etil]benzoil]-l-glutamico; sus sales farmacéuticamente aceptables y aplicaciones
UY39865A (es) Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer
AR131001A1 (es) Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
CO2023013406A2 (es) Análogos de rifamicina en combinación con vancomicina y usos de los mismos
MX2025012340A (es) Formas solidas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo
CL2025001592A1 (es) Formulación farmacéutica de un inhibidor pan-jak y uso para tratar afección inflamatoria.
KR20190063792A (ko) 슈반세포 분화용 배지 조성물 및 상기 배지 조성물을 이용한 체세포로부터 슈반세포로의 분화 방법